SHANGHAI, China I 04, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that the new drug application (NDA) has been accepted by the National ...

SHANGHAI, China I 4, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that the investigational new drug (IND) application for a phase 1b/2 ...

Following on from a period of exclusive evaluation announced in June 2024, Genmab has exercised its option to license an anti-glycan monoclonal antibody ...

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts ...

SOUTH SAN FRANCISCO, CA, USA I 05, 2024 I Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical ...

STOCKHOLM, Sweden I 5, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab ...

Multi-year effort leverages Muna's all-in-human MiND-MAP spatial multi-omics approach to identify and validate new drug targets and treatment pathways for ...

Studies will assess ST-067 in acute myeloid leukemia or myelodysplastic syndrome and in multiple myeloma. Preclinical data to be presented at the 2024 American Society of Hematolo ...

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics ...

MELBOURNE, Australia I 4, 2024 I Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company ...

BERLIN, Germany I 4, 2024 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...

Lilly is granted exclusive worldwide rights to develop a CD28-co-stimulatory therapeutic for a defined cancer target ...